Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. — ME/CFS Atlas
E2 ModeratePreliminaryPEM not requiredObservationalPeer-reviewedReviewed
Standard · 3 min
Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta.
This study found that people with ME/CFS have higher levels of a molecule called NF-kappa-beta in their white blood cells, both at rest and when stimulated by immune signals. This molecule controls inflammation and stress responses in cells. The higher the NF-kappa-beta levels, the more severe patients' symptoms—including fatigue, muscle pain, and feeling sick—were reported to be.
Why It Matters
This study provides biological evidence that ME/CFS involves real cellular inflammation rather than psychological causes, addressing long-standing stigma. By identifying NF-kappa-beta as a central regulatory mechanism, it offers a potential biological marker for disease severity and suggests testable therapeutic targets through antioxidant interventions.
Observed Findings
CFS patients had significantly higher unstimulated NF-kappa-beta p50 production compared to controls (F=19.4, p=0.0002)
TNF-alpha-stimulated NF-kappa-beta production was significantly elevated in CFS patients (F=14.0, p=0.0009)
PMA-stimulated NF-kappa-beta production was significantly elevated in CFS patients (F=7.9, p=0.008)
Positive correlations existed between NF-kappa-beta production levels and symptom severity measured by the FibroFatigue scale
NF-kappa-beta levels correlated positively with specific symptoms including fatigue, muscular tension, aches, pain, irritability, sadness, and subjective infection feeling
Inferred Conclusions
Intracellular inflammatory responses in white blood cells play an important role in ME/CFS pathophysiology
Previously observed increases in oxidative stress and inflammation in ME/CFS may be mediated by elevated NF-kappa-beta production
ME/CFS symptoms reflect a genuine biological inflammatory response rather than psychological or psychiatric etiology
Antioxidants that inhibit NF-kappa-beta production warrant investigation as potential treatments for ME/CFS
Remaining Questions
Does NF-kappa-beta elevation precede symptom onset, occur as a result of disease processes, or both?
What This Study Does Not Prove
This study does not establish that NF-kappa-beta elevation causes ME/CFS symptoms or that treating it will improve outcomes; it only shows correlation. The small sample size (n=18 per group) and cross-sectional design limit generalizability, and the study does not demonstrate whether NF-kappa-beta changes are primary drivers of pathology or secondary consequences of the disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.